Shanghai HeartCare Medical Technology (HKSE:06609) Beneish M-Score: -2.57 (As of Aug. 29, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:06609 Shanghai HeartCare Medical Technology Corp Ltd HKSE:06609
78 GF Score
Price HK$48.24
GF Value HK$54.80
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Shanghai HeartCare Medical Technology Beneish M-Score?

Shanghai HeartCare Medical Technology HKSE:06609 -4.29% 78 Beneish M-Score is -2.57 as of Aug. 29, 2026. GuruFocus rates HKSE:06609 with a GF Score™ of 78/100 and a GF Value™ of HK$54.80 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 772 Medical Devices & Instruments companies, Shanghai HeartCare Medical Technology ranks worse than 50.13% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.57 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Shanghai HeartCare Medical Technology's Beneish M-Score or its related term are showing as below:

HKSE:06609' s Beneish M-Score Range Over the Past 10 Years
Min: -2.57   Med: -1.89   Max: 6.14
Current: -2.57

During the past 7 years, the highest Beneish M-Score of Shanghai HeartCare Medical Technology was 6.14. The lowest was -2.57. And the median was -1.89.


Shanghai HeartCare Medical Technology Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Shanghai HeartCare Medical Technology's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shanghai HeartCare Medical Technology Beneish M-Score Chart

Shanghai HeartCare Medical Technology Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial 6.14 -1.89 -0.54 -2.40 -2.57

Shanghai HeartCare Medical Technology Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.54 0.00 -2.40 0.00 -2.57

HKSE:06609 vs ABT, SYK, MDT: Beneish M-Score Comparison

For the Medical Devices subindustry, Shanghai HeartCare Medical Technology's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shanghai HeartCare Medical Technology Beneish M-Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Shanghai HeartCare Medical Technology's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Shanghai HeartCare Medical Technology's Beneish M-Score falls into.


HKSE:06609
78GF Score
Shanghai HeartCare Medical Technology Corp Ltd HKSE:06609
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shanghai HeartCare Medical Technology Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Shanghai HeartCare Medical Technology for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.6667+0.528 * 0.9221+0.404 * 1.1481+0.892 * 1.5202+0.115 * 1.0907
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9242+4.679 * -0.054796-0.327 * 1.1017
=-2.57

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Total Receivables was HK$105.6 Mil.
Revenue was HK$451.0 Mil.
Gross Profit was HK$319.8 Mil.
Total Current Assets was HK$1,201.0 Mil.
Total Assets was HK$1,427.5 Mil.
Property, Plant and Equipment(Net PPE) was HK$89.4 Mil.
Depreciation, Depletion and Amortization(DDA) was HK$31.3 Mil.
Selling, General, & Admin. Expense(SGA) was HK$206.7 Mil.
Total Current Liabilities was HK$104.5 Mil.
Long-Term Debt & Capital Lease Obligation was HK$39.6 Mil.
Net Income was HK$92.1 Mil.
Gross Profit was HK$0.0 Mil.
Cash Flow from Operations was HK$170.3 Mil.
Total Receivables was HK$104.2 Mil.
Revenue was HK$296.7 Mil.
Gross Profit was HK$194.0 Mil.
Total Current Assets was HK$1,093.1 Mil.
Total Assets was HK$1,287.9 Mil.
Property, Plant and Equipment(Net PPE) was HK$87.1 Mil.
Depreciation, Depletion and Amortization(DDA) was HK$34.3 Mil.
Selling, General, & Admin. Expense(SGA) was HK$147.1 Mil.
Total Current Liabilities was HK$88.0 Mil.
Long-Term Debt & Capital Lease Obligation was HK$30.0 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(105.64 / 451.044) / (104.225 / 296.705)
=0.234212 / 0.351275
=0.6667

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(194.013 / 296.705) / (319.841 / 451.044)
=0.653892 / 0.709113
=0.9221

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (1201.017 + 89.426) / 1427.507) / (1 - (1093.081 + 87.096) / 1287.878)
=0.096016 / 0.083627
=1.1481

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=451.044 / 296.705
=1.5202

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(34.282 / (34.282 + 87.096)) / (31.25 / (31.25 + 89.426))
=0.28244 / 0.258958
=1.0907

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(206.715 / 451.044) / (147.131 / 296.705)
=0.458303 / 0.495883
=0.9242

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((39.587 + 104.487) / 1427.507) / ((29.979 + 88.003) / 1287.878)
=0.100927 / 0.09161
=1.1017

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(92.062 - 0 - 170.283) / 1427.507
=-0.054796

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Shanghai HeartCare Medical Technology has a M-score of -2.57 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.57 mean?
Shanghai HeartCare Medical Technology (HKSE:06609) has a Beneish M-Score of -2.57 as of Aug. 29, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Shanghai HeartCare Medical Technology and its competitors. According to the industry distribution chart, Shanghai HeartCare Medical Technology ranks #387 out of 772 companies in the Medical Devices & Instruments industry, placing it in the top 50.1%.
Is Shanghai HeartCare Medical Technology's Beneish M-Score too high?
Shanghai HeartCare Medical Technology's current Beneish M-Score is -2.57. Based on the distribution chart, Shanghai HeartCare Medical Technology ranks #387 out of 772 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Shanghai HeartCare Medical Technology has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai HeartCare Medical Technology's Beneish M-Score compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Shanghai HeartCare Medical Technology ranks #387 out of 772 companies for Beneish M-Score. This places Shanghai HeartCare Medical Technology in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Medical Devices & Instruments company?
A good Beneish M-Score depends on the Medical Devices & Instruments industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Shanghai HeartCare Medical Technology and its competitors. Shanghai HeartCare Medical Technology's current Beneish M-Score is -2.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai HeartCare Medical Technology stock overvalued right now?
Based on GuruFocus' analysis, Shanghai HeartCare Medical Technology (HKSE:06609) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$54.80, compared to a current price of HK$48.24 — trading 12% below its estimated fair value. The current Beneish M-Score is -2.57. Shanghai HeartCare Medical Technology's overall GF Score™ is 78/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Shanghai HeartCare Medical Technology (HKSE:06609), the current Beneish M-Score is -2.57 as of Aug. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shanghai HeartCare Medical Technology (HKSE:06609) Overvalued in 2026?

Based on GuruFocus' analysis, Shanghai HeartCare Medical Technology stock appears to be undervalued. The current stock price of HK$48.24 is trading 12% below its estimated GF Value™ of HK$54.80. GuruFocus considers Shanghai HeartCare Medical Technology to be Modestly Undervalued.

Key valuation signals for HKSE:06609:

  • Beneish M-Score: -2.57
  • GF Value™: HK$54.80 vs. price of HK$48.24 (12% below fair value)
  • GF Score™: 78/100 with 2 warning signs

No single metric tells the full story. See the HKSE:06609 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Shanghai HeartCare Medical Technology Business Description

Address No. 356, Zhengbo Road, Floor 1 and 3, Building 38, Pilot Free Trade Zone, Lingang New District, Shanghai, CHN
Shanghai HeartCare Medical Technology Corp Ltd is an neuro-interventional medical device company. The company is committed to creating high-quality products for the prevention and treatment of stroke. The company focuses on Research and development, manufacturing and commercialization to fulfill the unmet needs of clinicians and patients to redefine the standard of care, reduce mortality rate, and improve prognosis by continuously launching new medical devices. Geographically, the Group's majority revenue is derived from Chinese Mainland.
78GF Score

Get the complete analysis for HKSE:06609

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$48.24
Price
HK$54.80
GF Value